clarithromycin has been researched along with Ventilator-Associated Pneumonia in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adamopoulou, M; Giamarellos-Bourboulis, EJ; Kotanidou, A; Orfanos, SE; Raftogiannis, M; Renieris, G; Routsi, C; Sabracos, L; Strouvalis, I | 1 |
| Harada, Y; Hasegawa, H; Imamura, Y; Izumikawa, K; Kakeya, H; Kaku, N; Kohno, S; Mikamo, H; Miyazaki, T; Morinaga, Y; Nakamura, S; Uno, N; Yamada, K; Yanagihara, K | 1 |
| Armaganidis, A; Christodoulou, S; Giamarellos-Bourboulis, EJ; Kotanidou, A; Papadomichelakis, E; Pratikaki, M; Raftogiannis, M; Routsi, C; Tsaganos, T | 1 |
| Antonopoulou, A; Baziaka, F; Giamarellos-Bourboulis, EJ; Karagianni, V; Kotanidou, A; Koutoukas, P; Mouktaroudi, M; Netea, MG; Orfanos, SE; Pelekanou, A; Raftogiannis, M; Routsi, C; Spyridaki, A; Tsaganos, T; van der Meer, JW | 1 |
| Antonopoulou, A; Armaganidis, A; Baziaka, F; Giamarellos-Bourboulis, EJ; Giamarellou, H; Kollias, S; Koronaios, A; Kotanidou, A; Koussoulas, V; Koutoukas, P; Markaki, V; Papadomichelakis, E; Pechère, JC; Plachouras, D; Raftogiannis, M; Roussos, C; Routsi, C; Tsaganos, T; Zervakis, D | 1 |
4 trial(s) available for clarithromycin and Ventilator-Associated Pneumonia
| Article | Year |
|---|---|
Early increase of VEGF-A is associated with resolution of ventilator-associated pneumonia: Clinical and experimental evidence.
Topics: Animals; Anti-Bacterial Agents; APACHE; Biomarkers; Bronchoalveolar Lavage Fluid; Clarithromycin; Double-Blind Method; Humans; Interferon-gamma; Interleukin-1beta; Mice; Peroxidase; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Time Factors; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2018 |
Clarithromycin Leads to Long-Term Survival and Cost Benefit in Ventilator-Associated Pneumonia and Sepsis.
Topics: Administration, Intravenous; Adult; Anti-Infective Agents; Clarithromycin; Cost-Benefit Analysis; Double-Blind Method; Drug Administration Schedule; Female; Greece; Hospitalization; Humans; Intensive Care Units; Male; Middle Aged; Pneumonia, Ventilator-Associated; Prospective Studies; Sepsis; Survival Analysis; Survivors | 2016 |
Effect of clarithromycin in inflammatory markers of patients with ventilator-associated pneumonia and sepsis caused by Gram-negative bacteria: results from a randomized clinical study.
Topics: Apoptosis; B7-2 Antigen; CD40 Ligand; Clarithromycin; Double-Blind Method; Gram-Negative Bacteria; Humans; Interleukin-10; Interleukin-6; Pneumonia, Ventilator-Associated; Sepsis; Tumor Necrosis Factor-alpha | 2012 |
Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia.
Topics: Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Double-Blind Method; Female; Humans; Male; Middle Aged; Pneumonia, Ventilator-Associated; Sepsis; Treatment Outcome | 2008 |
1 other study(ies) available for clarithromycin and Ventilator-Associated Pneumonia
| Article | Year |
|---|---|
Azithromycin inhibits MUC5AC induction via multidrug-resistant Acinetobacter baumannii in human airway epithelial cells.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Azithromycin; Blotting, Western; Bronchi; Cells, Cultured; Clarithromycin; Drug Resistance, Multiple, Bacterial; Enzyme-Linked Immunosorbent Assay; Epithelial Cells; Gene Expression Regulation; Humans; Mucin 5AC; Pneumonia, Ventilator-Associated; Reverse Transcriptase Polymerase Chain Reaction | 2014 |